JGK-263

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameJGK-263
Drug Alias NameGSK inhibitor (Jeil)glycogen synthase inhibitor (Jeil)JGK program (Jeil)JGK-216JI-7263 +[6] 
ClassificationSmall molecules
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitorsApoptosis inhibitorsCNS modulators
TargetsGlycogen synthase kinase-3 beta
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJeil Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJeil Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNerve Degeneration

Other Information

ATC CodeN/A
Related LinksN/A